Chronic Angina may
be holding him back
For patients limiting their activity due to
chronic angina, adding Ranexa® may help
Ranexa 1000 mg BID*, when added to a beta-blocker
or calcium channel blocker, was superior to those
treatments plus placebo at:1,†
Increasing exercise duration
Increasing the time to onset of ischemia during exercise
testing at peak plasma concentrations
Decreasing angina frequency
Decreasing nitroglycerin use
Learn how to get your patients back on track with Ranexa
www.RanexaHCP.com
BID = twice daily
*Limit the dose of Ranexa to 500 mg BID when coadministered with diltiazem, verapamil, or other moderate CYP3A inhibitors.
†
CARISA TRIAL DESIGN: CARISA (Combination Assessment of Ranolazine In Stable Angina) was a double-blind,
randomized, placebo-controlled clinical trial of 823 patients with chronic angina who received Ranexa 750 mg BID (n = 272),
Ranexa 1000 mg BID (n = 261), or placebo (n = 258) for 12 weeks (note, 750 mg is not an approved dose). At the physician’s
discretion, patients received either atenolol 50 mg, amlodipine 5 mg, or diltiazem 180 mg once daily as required background
antianginal therapy. Sublingual nitrates were used as needed.
Please see following page for brief summary of
Full Prescribing Information.
daily and increase to the maximum
recommended dose of 1000 mg
twice daily, based on clinical
symptoms. Ranexa should be
swallowed whole; do not crush,
break or chew.
Limit the dose of Ranexa to
500 mg twice daily in patients on
moderate CYP3A inhibitors (e.g.,
diltiazem, verapamil, erythromycin,
fluconazole, and grapefruit juice or
grapefruit-containing products).
See Drug Interactions for additional
dosing considerations.
Drug Interactions
Inducers and strong inhibitors of
CYP3A: Do not use Ranexa
(see Contraindications).
Moderate CYP3A inhibitors: Limit
Ranexa to 500 mg twice daily (see
Dosage and Administration).
P-gp inhibitors (e.g.,
cyclosporine): Ranexa exposure
increased; titrate Ranexa based on
clinical response.
CYP3A substrates: Limit simvastatin
to 20 mg once daily when used with
Ranexa. Doses of other sensitive
CYP3A substrates (e.g., lovastatin)
and CYP3A substrates with narrow
therapeutic range (e.g., cyclosporine,
tacrolimus, sirolimus) may need to be
reduced with Ranexa
Drugs transported by P-gp
(e.g., digoxin) or metabolized
by CYP2D6 (e.g., tricyclic
antidepressants and
antipsychotics): Doses of these
drugs may need to be reduced.
Drugs transported by OCT2:
Limit metformin to 1700 mg per day
when used with Ranexa 1000 mg
twice daily. Monitor blood glucose
and risks associated with high
metformin exposure.
References: 1. Chaitman BR, Pepine CJ, Parker JO,
et al. Effects of ranolazine with atenolol, amlodipine, or
diltiazem on exercise tolerance and angina frequency
in patients with severe chronic angina: a randomized
controlled trial. JAMA. 2004;291:309-316.
Ranexa is a registered trademark of Gilead Palo Alto, Inc.
@2015 Gilead Sciences, Inc. All rights reserved. RANP0285 09/15